FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to transplantology and cardiovascular surgery, and can be used for prediction of risk of calcification of biological prostheses of cardiac valves. If the period of operation of the prosthesis is less than 4 years, the following is to be determined for the patient: sex, age, value of serum concentration of alkaline phosphatase, level of bone isoenzyme of alkaline phosphatase, duration of operation of the biological prosthesis in years. Probable risk (P) of calcification is determined by formula. If P is equal to 0-0.5, low risk of calcification is predicted. If P is from 0.5 to 0.6 - average risk. If P values are within 0.6-1.0, high risk of the implant calcification is probable. If the period of operation of the prosthesis from 4 to 8 years, to be determined are: value of serum osteocalcin of the patient, level of parathyroid hormone, phosphorus content in blood serum. Probable risk (P) of calcification is determined by formula. Low risk of calcification is predicted if P values are from 0 to 0.3. Average risk is predicted if P is within 0.3-0.5. To the high-risk group patients join with P values of 0.5-1. If the period of operation of the prosthesis is more than 8 years, to be determined are: phosphorus content in blood serum, value of calcium-phosphorus ratio, level of bone isoenzyme of alkaline phosphatase. Probable risk (P) of calcification is determined by formula, and low risk is predicted if P is within 0-0.4. Average risk stands for P within 0.4-0.6. High risk of calcification stands for P from 0.6 to 1.0.
EFFECT: group of inventions allows precise prediction of risk of calcification of biological prostheses of cardiac valves by assessing the most significant parameters.
3 cl, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING RISK OF CALCIFICATION OF BIOLOGICAL PROSTHESIS OF HEART VALVES, IMPLANTED IN MITRAL POSITION, BASING ON GENOMIC PREDICTORS | 2016 |
|
RU2616507C1 |
METHOD FOR ASSESSING ACTIVITY OF SCLERO-DEGENERATIVE PROCESSES OF BIOPROSTHESES OF HEART VALVES | 2023 |
|
RU2816076C1 |
METHOD FOR MITRAL VALVE THORACOSCOPIC TRANSCATHETER REPROTHESIS BY SELF-DEPLOYING BIOLOGICAL PROTHESIS (VERSIONS) | 2016 |
|
RU2632540C1 |
METHOD OF MITRAL VALVE REPLACEMENT WITH AUTOPERICARDIUM | 2022 |
|
RU2804993C1 |
METHOD OF MAKING VALVE BIOPROTESIS OF HEART VALVE ON FLEXIBLE BASE FRAMEWORK WITH LOW PROFILE | 2017 |
|
RU2698983C2 |
METHOD FOR CONSERVATION OF BIOLOGICAL TISSUES FOR PROSTHETICS OF HEART AND VESSEL VALVES | 1992 |
|
RU2008767C1 |
METHOD FOR WIDENING FIBROUS RING OF AORTAL VALVE | 2000 |
|
RU2196515C2 |
EXTRACARDIAC VALVE-CONTAINING CONDUIT AND METHOD FOR PRODUCING IT | 2001 |
|
RU2202991C2 |
TRANSCATHETER THORACOSCOPIC METHOD FOR MITRAL VALVE REPLACEMENT IN PATIENTS WITH EXTREME RISK OF SURGICAL TREATMENT (OPTIONS) | 2017 |
|
RU2675068C1 |
METHOD FOR PREDICTION OF COMPLICATIONS ASSOCIATED WITH CONDITION OF PROSTHESIS AND AORTIC ROOT AFTER TRANSCATHETER IMPLANTATION OF AORTIC VALVE BY COMPUTED TOMOGRAPHY | 2023 |
|
RU2820224C1 |
Authors
Dates
2016-09-10—Published
2015-06-17—Filed